WO2005092321A1 - 頻尿または尿失禁の予防または治療用医薬組成物 - Google Patents
頻尿または尿失禁の予防または治療用医薬組成物 Download PDFInfo
- Publication number
- WO2005092321A1 WO2005092321A1 PCT/JP2004/004000 JP2004004000W WO2005092321A1 WO 2005092321 A1 WO2005092321 A1 WO 2005092321A1 JP 2004004000 W JP2004004000 W JP 2004004000W WO 2005092321 A1 WO2005092321 A1 WO 2005092321A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pharmaceutical composition
- treatment
- acid
- general formula
- prevention
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
Definitions
- the present invention relates to a pharmaceutical composition useful for the prevention or treatment of frequent urination or urinary incontinence.
- the present invention provides a general formula
- R 1 is a hydroxyl group or a lower alkoxy group
- a phenoxyacetic acid derivative represented by the formula:
- anticholinergic drugs which are the center of pharmacotherapy, are concerned about side effects such as rheumatoid arthritis, constipation, drainage disorders, central nervous system symptoms, etc., and may not be able to continue treatment or may have insufficient therapeutic effects (Scope, Falumasia Corporation, 2003, Volume 42, No. 1, p. 14-15).
- S 3 adrenergic receptor (hereinafter / 3 3 -AR) stimulating book A series of compounds including phenoxyacetic acid derivatives represented by the above general formula (I) of the invention and pharmacologically acceptable salts thereof have been developed to relax bladder detrusor muscles and increase bladder capacity to store urine A new prophylactic or therapeutic agent for pollakiuria, urinary incontinence and the like by exerting an effect of increasing the amount has been proposed (International Publication No. 00/02846).
- ⁇ -AR is mainly distributed in smooth muscles such as the prostate and urethra, and 1-AR increases due to prostatic hypertrophy, but 1-AR blockers have a 1-AR blocking action to prevent urethral smoothness.
- the combination of the compound represented by the general formula (I) having / 3 3 -AR stimulating action and the ⁇ -AR blocker significantly reduces the intravesical pressure, and frequently There is no mention or suggestion that it is very useful in the prevention or treatment of urine or urinary incontinence.
- the present inventors have found that a combination of the compound represented by the general formula (I) and a Q! L-AR blocker is The present inventors have achieved the knowledge that it has an unexpectedly remarkable effect of reducing intravesical pressure and is extremely useful for the prevention or treatment of frequent urination or urinary incontinence.
- the present invention uses the following phenoxyacetic acid derivative or a pharmacologically acceptable salt thereof in combination with a Q! 1 -AR blocker to produce an excellent frequent decrease in bladder pressure. It provides a pharmaceutical composition for preventing or treating urine or urinary incontinence.
- Phenoxyacetic acid derivative represented by: or a pharmacologically acceptable salt thereof, and a frequent urination or a i-AR blocker used in combination A pharmaceutical composition for the prevention or treatment of urinary incontinence;
- the compound represented by the general formula (I) is (1) —2— [4— [2— [[(IS, 2R) —2—hydroxy— 2— (4-hydroxyphenyl) 1-methylethyl] amino] ethyl] 1,2,5-dimethylphenoxy] ethyl acetate, the pharmaceutical composition according to (1) above;
- the present invention will be described in detail in the following rat anesthetized rat intravesical pressure test:
- the combined administration of the compound represented by the general formula (I) and the ⁇ ⁇ -AR blocker exerted a remarkable intravesical pressure lowering effect as compared with the single agent administration.
- the pharmaceutical composition of the present invention exhibits an excellent bladder relaxing action, increases the bladder capacity, and increases the amount of urine stored. Therefore, the pharmaceutical composition of the present invention is extremely useful as a preventive or therapeutic agent for frequent urination or urinary incontinence.
- the pharmaceutical composition of the present invention significantly reduces intravesical pressure, and is optimal for the prevention or treatment of frequent urination or urinary incontinence.
- frequent urination or urinary incontinence include neural urinary frequency, nocturia, frequent urinary incontinence due to prostatic hypertrophy, idiopathic urinary incontinence, urinary incontinence, etc.
- the pharmaceutical composition used in combination in the present invention can exert a very powerful effect, it is effective for patients who are not effective with a single agent, patients who want to reduce the dose of the drug used for the disease, etc. Can be expected to be an effective therapeutic agent.
- the lower alkoxy group means methoxy group, ethoxy group, propoxy group, butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, isopentyl group, hexyl group, etc. And linear and branched alkoxy groups.
- preferable compounds include, for example, (—) 1 2- [4— [2— [[(IS, 2R) —2—hydroxy— 2— (4— Hydroxyphenyl) 1-1-methylethyl] amino] ethyl] -1,5-dimethylphenoxy] ethyl acetate (Compound 1) and pharmacologically acceptable salts thereof.
- Various methods for producing the compound represented by the general formula (I) are known, and can be produced by methods described in the literature (for example, see International Publication No. 00/02846).
- the compound represented by the general formula (I) can be converted into a pharmacologically acceptable salt thereof by a conventional method.
- salts include acid addition salts with inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, P-toluenesulfonic acid, propionic acid, Acid addition salts with sodium citrate, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, aspartic acid, sodium salt, potassium salt, Examples thereof include inorganic base salts such as calcium salts, and salts with organic bases such as triethylamine, piperidine, morpholine, pyridine, and lysine.
- inorganic acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid, for
- the compound represented by the general formula (I) includes solvates with pharmaceutically acceptable solvents such as hydrates and ethanol, and crystal polymorphs thereof.
- Examples of the 0! 1-AR blocker that can be used in combination with the compound represented by the general formula (I) include, for example, evening mucin, prazosin, terazosin, naphthovir, silodosin, etc. They can also be used as pharmacologically acceptable salts thereof. Preferable examples include musk mouth cin, silodosin and pharmacologically acceptable salts thereof. These drugs are expected to reduce the risk of side effects due to their high selectivity for ⁇ ⁇ -AR.
- the present invention provides simultaneous administration as a single preparation, the same as separate preparations or
- the pharmaceutical composition of the present invention includes a single dosage form as described above, including simultaneous administration by different administration routes, and administration forms separated by the same or different administration routes as separate preparations. And dosage forms that combine separate preparations.
- dosage forms are used depending on the usage.
- dosage forms include powders, granules, fine granules, dry syrups, tablets, capsules, injections, solutions, ointments, suppositories, patches, etc. It is administered orally.
- compositions are suitable excipients, disintegrants, binders, lubricants, diluents, buffers, isotonic agents, preservatives, depending on the method used in pharmacology depending on the dosage form. It can be produced by mixing or diluting / dissolving appropriately with pharmaceutical additives such as wetting agents, emulsifiers, dispersants, stabilizers, solubilizers, etc., and dispensing according to conventional methods. Ma When other drugs are used in combination, they can be produced by formulating each active ingredient simultaneously or separately in the same manner as described above.
- the dosage is the patient's body weight, age, sex, It is determined as appropriate depending on the degree of the disease and the effect of the ai-AR blocker used in combination, but for oral administration it is generally in the range of 1-1000 mg per day, and for parenteral administration, adult It is generally in the range of 0.01 mg / day to LOO mg per day, and can be appropriately administered in one or several divided doses.
- the dosage of the above-mentioned 1-AR blocker used in combination with the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof is, for each drug, administration route, disease symptom. It is determined as appropriate considering the weight, age, sex, etc. of the subject patient.
- the daily active ingredient is approximately 25 to 150 mg for naphthopidyl, approximately 1 to 12 mg for prazosin hydrochloride, approximately 0.1 to 0.8 mg for musk mouth levern, and silodosin. 'Approximately 1 to 16 mg, and can be administered in a single dose or divided into several doses.
- the combination pharmaceutical composition of the present invention may be used in combination with another urination disorder therapeutic agent or at a time as necessary.
- Other dysuria drugs include, for example, anticholinergic drugs,] 3 2 adrenergic receptor agonists, estrogen preparations, central nervous system drugs (selective serotonin reuptake inhibitors, serotonin / norepinephrine reuptake inhibitors, etc.), Neurokinin receptor antagonist, force rheumatic channel opener, vanilloid receptor agonist, vasopressin 2 receptor agonist, GABA receptor agonist, serotonin receptor antagonist, dopamine receptor agonist, antiallergic agent, nonsteroidal anti-inflammatory analgesic, Examples include NO synthesis inhibitors.
- Example 1 The contents of the present invention will be described in more detail in the following examples, but the present invention is not limited to the contents.
- Example 1 The contents of the present invention will be described in more detail in the following examples, but the present invention is not limited to the contents.
- Fig. 1 shows the intravesical pressure-reducing action of each drug in anesthetized rats.
- the bar graph shows data from the left for tamsulosin hydrochloride alone, compound 1 alone, and mus mucin in the evening.
- the vertical axis shows the bladder pressure lowering effect as a percentage of the maximum lowering effect by isoproterenol.
- a pharmaceutical composition comprising a combination of the compound represented by the general formula (I) or a pharmacologically acceptable salt thereof and an ⁇ 1 -AR blocking agent exhibits an excellent action for reducing intravesical pressure. Therefore, the present invention can provide a prophylactic or therapeutic agent extremely useful for frequent urination or urinary incontinence.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/004000 WO2005092321A1 (ja) | 2004-03-24 | 2004-03-24 | 頻尿または尿失禁の予防または治療用医薬組成物 |
PCT/JP2005/004825 WO2005089742A1 (ja) | 2004-03-24 | 2005-03-17 | 頻尿または尿失禁の予防または治療用医薬 |
ES05721012T ES2331369T3 (es) | 2004-03-24 | 2005-03-17 | Medicina para prevencion o tratamiento de miccion frecuente o incontinencia urinaria. |
DK05721012.2T DK1728508T3 (da) | 2004-03-24 | 2005-03-17 | Farmaceutisk produkt til forebyggelse eller behandling af hyppig vandladning eller inkontinens |
AT05721012T ATE442137T1 (de) | 2004-03-24 | 2005-03-17 | Medikament zur prävention oder behandlung von häufigem harndrang oder harninkontinenz |
PL05721012T PL1728508T3 (pl) | 2004-03-24 | 2005-03-17 | Lek użyteczny do zapobiegania lub leczenia częstomoczu lub nietrzymania moczu |
PT05721012T PT1728508E (pt) | 2004-03-24 | 2005-03-17 | Medicamento para prevenção ou tratamento de micção frequente ou incontinência urinária |
US10/599,203 US20080242674A1 (en) | 2004-03-24 | 2005-03-17 | Medicine For Prevention or Treatment of Frequent Urination or Urinary Incontinence |
SI200530851T SI1728508T1 (sl) | 2004-03-24 | 2005-03-17 | Zdravilo za preprečevanje ali zdravljenje pogostega uriniranja ali urinske inkontinence |
EP05721012A EP1728508B1 (en) | 2004-03-24 | 2005-03-17 | Medicine for prevention or treatment of frequent urination or urinary incontinence |
CA002559646A CA2559646A1 (en) | 2004-03-24 | 2005-03-17 | Medicine for prevention or treatment of frequent urination or urinary incontinence |
JP2006511224A JP4808613B2 (ja) | 2004-03-24 | 2005-03-17 | 頻尿または尿失禁の予防または治療用医薬 |
DE602005016534T DE602005016534D1 (de) | 2004-03-24 | 2005-03-17 | Medikament zur prävention oder behandlung von häufigem harndrang oder harninkontinenz |
CY20091101275T CY1109546T1 (el) | 2004-03-24 | 2009-12-04 | Φαρμακο για την προληψη η θεραπεια της συχνουριας η της ουρικης ακρατειας |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2004/004000 WO2005092321A1 (ja) | 2004-03-24 | 2004-03-24 | 頻尿または尿失禁の予防または治療用医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005092321A1 true WO2005092321A1 (ja) | 2005-10-06 |
Family
ID=34993428
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/004000 WO2005092321A1 (ja) | 2004-03-24 | 2004-03-24 | 頻尿または尿失禁の予防または治療用医薬組成物 |
PCT/JP2005/004825 WO2005089742A1 (ja) | 2004-03-24 | 2005-03-17 | 頻尿または尿失禁の予防または治療用医薬 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/004825 WO2005089742A1 (ja) | 2004-03-24 | 2005-03-17 | 頻尿または尿失禁の予防または治療用医薬 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20080242674A1 (ja) |
EP (1) | EP1728508B1 (ja) |
AT (1) | ATE442137T1 (ja) |
CA (1) | CA2559646A1 (ja) |
CY (1) | CY1109546T1 (ja) |
DE (1) | DE602005016534D1 (ja) |
DK (1) | DK1728508T3 (ja) |
ES (1) | ES2331369T3 (ja) |
PL (1) | PL1728508T3 (ja) |
PT (1) | PT1728508E (ja) |
SI (1) | SI1728508T1 (ja) |
WO (2) | WO2005092321A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1769792A1 (de) * | 2005-09-30 | 2007-04-04 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verwendung eines beta-3-Adrenozeptor-Agonisten zur Behandlung von Nieren- und Blasenbeschwerden |
FR2895259B1 (fr) * | 2005-12-22 | 2008-02-22 | Urosphere Sas | Methodes de traitement des incontinences urinaires |
WO2008106125A2 (en) | 2007-02-26 | 2008-09-04 | Concert Pharmaceuticals, Inc. | Deuterated derivatives of silodosin as alpha la-adrenoceptor antagonists |
US20100210668A1 (en) * | 2007-10-02 | 2010-08-19 | Dong-A Pharm. Co., Ltd. | Composition and method for treatment or prevention of benign prostatic hyperplasia and lower urinary tract symptoms |
US20110262566A1 (en) * | 2008-11-07 | 2011-10-27 | Dainippon Sumitomo Pharma Co., Ltd. | Novel useful therapeutic agent for lower urinary tract symptom |
JP5426801B2 (ja) * | 2011-08-25 | 2014-02-26 | キッセイ薬品工業株式会社 | 低活動膀胱の予防または治療用医薬組成物 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000002846A1 (en) * | 1998-07-08 | 2000-01-20 | Kissei Pharmaceutical Co., Ltd. | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
JP2001114679A (ja) * | 1999-08-09 | 2001-04-24 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
WO2002069906A2 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
JP2003055261A (ja) * | 2001-08-08 | 2003-02-26 | Pfizer Prod Inc | 製剤組合せ |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6426517A (en) * | 1987-07-21 | 1989-01-27 | Sankyo Co | Remedy for dysuria |
SE504276C2 (sv) * | 1993-12-30 | 1996-12-23 | Siko Medical Ab | Ventil avsedd att placeras i urinröret |
US6262115B1 (en) * | 1995-05-22 | 2001-07-17 | Alza Coporation | Method for the management of incontinence |
US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
US6410554B1 (en) * | 1998-03-23 | 2002-06-25 | Merck & Co., Inc. | Combination therapy for the treatment of benign prostatic hyperplasia |
IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
JP4132020B2 (ja) * | 2001-03-12 | 2008-08-13 | キッセイ薬品工業株式会社 | フェノキシ酢酸誘導体の製造中間体およびその使用方法 |
HUP0401694A3 (en) * | 2001-09-13 | 2008-03-28 | Kissei Pharmaceutical | Crystal forms of a hydrochloride salt of a hydroxynorephedrine derivative, pharmaceutical compositions comprising thereof and use |
AU2004285289A1 (en) | 2003-11-03 | 2005-05-12 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition, containing a beta-3-adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor |
CA2557758C (en) * | 2004-03-05 | 2013-09-10 | Kissei Pharmaceutical Co., Ltd. | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder |
-
2004
- 2004-03-24 WO PCT/JP2004/004000 patent/WO2005092321A1/ja active Application Filing
-
2005
- 2005-03-17 PT PT05721012T patent/PT1728508E/pt unknown
- 2005-03-17 US US10/599,203 patent/US20080242674A1/en not_active Abandoned
- 2005-03-17 SI SI200530851T patent/SI1728508T1/sl unknown
- 2005-03-17 DE DE602005016534T patent/DE602005016534D1/de active Active
- 2005-03-17 CA CA002559646A patent/CA2559646A1/en not_active Abandoned
- 2005-03-17 ES ES05721012T patent/ES2331369T3/es active Active
- 2005-03-17 DK DK05721012.2T patent/DK1728508T3/da active
- 2005-03-17 EP EP05721012A patent/EP1728508B1/en not_active Not-in-force
- 2005-03-17 AT AT05721012T patent/ATE442137T1/de active
- 2005-03-17 WO PCT/JP2005/004825 patent/WO2005089742A1/ja not_active Application Discontinuation
- 2005-03-17 PL PL05721012T patent/PL1728508T3/pl unknown
-
2009
- 2009-12-04 CY CY20091101275T patent/CY1109546T1/el unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000002846A1 (en) * | 1998-07-08 | 2000-01-20 | Kissei Pharmaceutical Co., Ltd. | Phenoxyacetic acid derivatives and medicinal compositions containing the same |
JP2001114679A (ja) * | 1999-08-09 | 2001-04-24 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
JP2001288115A (ja) * | 2001-02-07 | 2001-10-16 | Yamanouchi Pharmaceut Co Ltd | 下部尿路症治療剤 |
WO2002069906A2 (en) * | 2001-03-06 | 2002-09-12 | Cellegy Pharmaceuticals, Inc. | Compounds and methods for the treatment of urogenital disorders |
JP2003055261A (ja) * | 2001-08-08 | 2003-02-26 | Pfizer Prod Inc | 製剤組合せ |
Also Published As
Publication number | Publication date |
---|---|
DE602005016534D1 (de) | 2009-10-22 |
PT1728508E (pt) | 2009-10-20 |
EP1728508A1 (en) | 2006-12-06 |
ES2331369T3 (es) | 2009-12-30 |
CY1109546T1 (el) | 2014-08-13 |
EP1728508B1 (en) | 2009-09-09 |
EP1728508A4 (en) | 2008-02-13 |
DK1728508T3 (da) | 2010-01-25 |
WO2005089742A8 (ja) | 2005-11-03 |
US20080242674A1 (en) | 2008-10-02 |
PL1728508T3 (pl) | 2010-02-26 |
CA2559646A1 (en) | 2005-09-29 |
SI1728508T1 (sl) | 2010-01-29 |
WO2005089742A1 (ja) | 2005-09-29 |
ATE442137T1 (de) | 2009-09-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050148632A1 (en) | Therapeutic agent for intestinal diseases and visceral pain | |
EP1728508B1 (en) | Medicine for prevention or treatment of frequent urination or urinary incontinence | |
WO2003006019A1 (fr) | Composition medicinale destinee au traitement de la cystite interstitielle | |
EP1557166A1 (en) | Alpha-aminoamide derivatives useful in the treatment of lower urinary tract disorders | |
JP2012507484A (ja) | αアドレナリン受容体拮抗薬と抗ムスカリン薬の併用 | |
EP1724257B1 (en) | Medicinal composition for prevention or treatment of overactive bladder accompanying nervous disorder | |
US20080027072A1 (en) | Potentiation of MC4 receptor activity | |
JP2603566B2 (ja) | 尿失禁治療剤 | |
US20100137399A1 (en) | Preventive and/or therapeutic agent for urine collection disorder accompanying lower urinary tract obstruction | |
JP5313686B2 (ja) | 失禁治療方法 | |
EP2172201A1 (en) | Pharmaceutical composition for amelioration of lower urinary tract symptom associated with prostatomegaly | |
JP4808613B2 (ja) | 頻尿または尿失禁の予防または治療用医薬 | |
US20040142929A1 (en) | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence | |
WO2006051797A1 (ja) | 間質性膀胱炎の治療薬 | |
WO2005000356A1 (ja) | 尿路疾患治療剤 | |
KR20020012314A (ko) | 빈뇨 혹은 요실금의 치료 또는 예방제 | |
KR102676631B1 (ko) | 과민성 방광의 예방 또는 치료용 약학적 조성물 | |
TW200409632A (en) | Phenylalkylamines and pyridylalkylamines | |
DK2810936T3 (en) | Hitherto-unknown acetic acid ester compound or salt thereof | |
US6864262B2 (en) | 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl) piperazine and pharmaceutically acceptable salts and solvents thereof | |
CN102869645A (zh) | 用于治疗肠易激综合征的方法和组合物 | |
AU2014271739B2 (en) | Novel fluorinated benzilic acid ester compound, and salt thereof | |
WO2005055999A1 (ja) | 抗コリン作用剤 | |
JP2005200303A (ja) | 尿失禁治療薬 | |
US20090036496A1 (en) | Treatment of Stress Urinary Incontinence and Mixed Urinary Incontinence |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: DE |
|
122 | Ep: pct application non-entry in european phase |